N. Varol

433 total citations
26 papers, 294 citations indexed

About

N. Varol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, N. Varol has authored 26 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Economics and Econometrics. Recurrent topics in N. Varol's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). N. Varol is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). N. Varol collaborates with scholars based in United Kingdom, United States and Germany. N. Varol's co-authors include Sarah Goring, Ellen Korol, Kristina S. Boye, James L. Palmer, V. Foos, Frank Griesinger, Phil McEwan, Sheena Kayaniyil, David Grant and Bradley Curtis and has published in prestigious journals such as Annals of Oncology, BMC Cancer and Cancers.

In The Last Decade

N. Varol

23 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Varol United Kingdom	7	137	89	76	57	37	26	294
Mari‐Anne Rowlands United Kingdom	8	147 1.1×	119 1.3×	130 1.7×	146 2.6×	28 0.8×	9	394
Carol Pearce United States	5	84 0.6×	96 1.1×	145 1.9×	124 2.2×	17 0.5×	6	326
Christiane D. Thienelt United States	7	58 0.4×	159 1.8×	170 2.2×	83 1.5×	39 1.1×	12	474
N. E. Allen United Kingdom	5	93 0.7×	157 1.8×	61 0.8×	123 2.2×	15 0.4×	7	325
Sayeh Lavasani United States	9	34 0.2×	163 1.8×	59 0.8×	57 1.0×	50 1.4×	24	303
Alice Nervo Italy	11	197 1.4×	77 0.9×	60 0.8×	25 0.4×	87 2.4×	20	326
NL Keating United States	4	60 0.4×	59 0.7×	102 1.3×	20 0.4×	11 0.3×	11	193
A. Gentry-Maharaj United Kingdom	6	91 0.7×	63 0.7×	30 0.4×	69 1.2×	16 0.4×	15	316
Heather Beckwith United States	11	50 0.4×	180 2.0×	58 0.8×	95 1.7×	30 0.8×	22	365
Samia Asif United States	7	151 1.1×	44 0.5×	50 0.7×	63 1.1×	23 0.6×	28	297

Countries citing papers authored by N. Varol

Since Specialization

Citations

This map shows the geographic impact of N. Varol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Varol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Varol more than expected).

Fields of papers citing papers by N. Varol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Varol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Varol. The network helps show where N. Varol may publish in the future.

Co-authorship network of co-authors of N. Varol

This figure shows the co-authorship network connecting the top 25 collaborators of N. Varol. A scholar is included among the top collaborators of N. Varol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Varol. N. Varol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Girard, Nicolas, Lien Vo, Mohammad A. Chaudhary, et al.. (2024). Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers. 16(13). 2492–2492.

Reck, Martin, Luis Paz‐Ares, Yong Yuan, et al.. (2024). Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 25(7). e362–e368.

O’Byrne, Kenneth J., Evan Popoff, Firas Badin, et al.. (2023). EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis. Journal of Thoracic Oncology. 18(11). S629–S630.

Goring, Sarah, et al.. (2023). P15 Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched "Time Zero": Methodology and Application in Resectable Non-Small Cell Lung Cancer. Value in Health. 26(6). S4–S4. 1 indexed citations

Lee, Adam, et al.. (2023). Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 23(1). 603–603. 7 indexed citations

Reck, Martin, et al.. (2022). 1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer. Annals of Oncology. 33. S1024–S1024. 1 indexed citations

Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2022). Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Journal of Medical Economics. 25(1). 703–711. 5 indexed citations

Lee, Adam, et al.. (2022). Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. Cancer Treatment and Research Communications. 33. 100648–100648. 5 indexed citations

Maervoet, Johan, Yong Yuan, Mohammad A. Chaudhary, et al.. (2021). EC1 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States. Value in Health. 24. S5–S5. 1 indexed citations

10.

Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2021). MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States. Journal of Thoracic Oncology. 16(1). S15–S16. 1 indexed citations

11.

Eccles, Laura J., et al.. (2021). 107P The evolving diagnostic and treatment landscape in metastatic non-small cell lung cancer (mNSCLC) across Europe: A real world evidence survey. Annals of Oncology. 32. S1421–S1421. 1 indexed citations

12.

Goring, Sarah, et al.. (2020). PCN39 TREATMENT EFFECT MODIFICATION OF IMMUNOTHERAPY-BASED REGIMENS IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS (RCTS). Value in Health. 23. S29–S29. 1 indexed citations

13.

Chaudhary, Mohammad A., Xiaowu Sun, Yong Yuan, N. Varol, & J.R. Penrod. (2020). PCN91 Estimating EQ-5D Utilities for Cost-Effectiveness Models Involving Immuno-Oncology Treatments. Value in Health. 23. S438–S438. 1 indexed citations

14.

Griesinger, Frank, et al.. (2019). Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer. 135. 196–204. 88 indexed citations

15.

Varol, N., et al.. (2018). Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK. International Journal of COPD. Volume 13. 2707–2720. 6 indexed citations

16.

Varol, N., Nathalie Waser, Juliette C. Thompson, et al.. (2018). PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC ASSESSMENT OF TRIAL DATA. Value in Health. 21. S23–S23. 1 indexed citations

17.

Hawkins, Neil, John F. Thompson, David A. Scott, et al.. (2014). Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes. Value in Health. 17(7). A335–A335. 2 indexed citations

18.

McEwan, Phil, V. Foos, David Grant, et al.. (2013). Predicting the Frequency of Severe and Non-Severe Hypoglycaemia in Insulin Treated Type-2 Diabetes Subjects. Value in Health. 16(7). A435–A435. 3 indexed citations

19.

Foos, V., David Grant, J. Lynn Palmer, et al.. (2013). Quantifying the Direct and Indirect Costs Associated with Severe and Non-Severe Hypoglycaemia in Subjects with Type-2 Diabetes Who Are Treated with Insulin. Value in Health. 16(7). A436–A437. 1 indexed citations

20.

Varol, N., et al.. (2012). PDB37 Cost-Effectiveness of Adding Twice-Daily Exenatide to Basal Insulin in Patients With Type 2 Diabetes in Scotland. Value in Health. 15(7). A500–A500. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact